Detection of 11 germline inactivating TP53 mutations and absence of TP63 and HCHK2 mutations in 17 French families with Li-Fraumeni or Li-Fraumeni-like syndrome

od BOUGEARD, G., LIMACHER, J., MARTIN, C., CHARBONNIER, F., KILLIAN, A., DELATTRE, O., LONGY, M., JONVEAUX, P., FRICKER, J., STOPPA-LYONNET, D., FLAMAN, J., FREBOURG, T.
Izdano 2001

Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li‐Fraumeni syndrome

od Bougeard, G, Baert‐Desurmont, S, Tournier, I, Vasseur, S, Martin, C, Brugieres, L, Chompret, A, Paillerets, B Bressac‐de, Stoppa‐Lyonnet, D, Bonaiti‐Pellie, C, Frebourg, T
Izdano 2006

TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy

od Oden-Gangloff, A, Di Fiore, F, Bibeau, F, Lamy, A, Bougeard, G, Charbonnier, F, Blanchard, F, Tougeron, D, Ychou, M, Boissière, F, Le Pessot, F, Sabourin, J-C, Tuech, J-J, Michel, P, Frebourg, T
Izdano 2009